Dr. Phillip A. Dennis was an Echols Scholar at the University of Virginia and received his B.A. with High Distinction in 1984. He received his M.D. and Ph.D. degrees from the New York University School of Medicineas part of the Medical Scientist Training Program. He went on to complete his internship and residency training in the Department of Medicine at Johns Hopkins Hospital. From 1995 to 1996, Dr. Dennis completed a fellowship in medical oncology at the Johns Hopkins Oncology Center. In 1999, Dr. Dennis joined NIH as a tenure-track investigator in the Signal Transduction Section, and in 2005 became a tenured Senior Investigator and the Clinical Service Director at NCI/Navy Medical Oncology. In 2012, Dr. Dennis moved to Johns Hopkins, where he served as the Director of the Center of Excellence in Thoracic Oncology and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview. Recently, Dr. Dennis joined AstraZeneca as Vice President, Disease Strategy Head, Lung Cancer in Global Medicines Development.
Dr. Dennis is a recipient of several awards and honors including the Alton Ochsner Award Relating Smoking and Health and an NIH Merit Award. He is an elected member of the American Society for Clinical Investigation, and is an invited contributor on the U.S. Surgeon General’s Report on How Tobacco Causes Disease – The Biology and Behavioral Basis for Tobacco-Attributable Disease. Dr. Dennis presently serves on six editorial boards and has served on numerous review and external advisory committees.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.